Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21670414 | 1.00 | KDM4E (0.31) | KDM4EMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL24328587 | 0.81 | DRD4 (0.35) | KDM4EMEN1KMT2A | |
| SCHEMBL24328040 | 0.78 | KDM4E (0.31) | KDM4EMEN1KMT2A | |
| SCHEMBL24328697 | 0.76 | TP53 (0.31) | — | |
| SCHEMBL24329220 | 0.72 | SMARCA4 (0.32) | — | |
| SCHEMBL22070061 | 0.69 | DRD4 (0.39) | KDM4EMEN1KMT2A | |
| SCHEMBL21670417 | 0.68 | CYP11B2 (0.48) | — | |
| SCHEMBL13100853 | 0.67 | MEN1 (0.44) | KDM4EMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL10192460 | 0.66 | — | — | |
| SCHEMBL24328037 | 0.65 | CYP11B2 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12428423-B2 | 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2025-09-30 | — | — | US | disclosed |
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS (JIANGSU) LTD. (CN) | 2022-10-06 | — | — | US | disclosed |
| EP-3608321-B1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | SHENGKE PHARMACEUTICALS JIANGSU LTD (CN) | 2022-09-07 | — | — | EP | disclosed |
| EP-3608321-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | Shengke Pharmaceuticals (Jiangsu) Ltd. (CN) | 2020-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315584-A1 | 1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR | CDK4, CDK2, CDKL1 | KDM4E 784/4885MEN1 2252/4885KMT2A 610/4885 |
| US-12428423-B2 | 1H-imidazo[4,5-h]quinazoline compound as protein kinase inhibitor | CDK4, CDK2, CDKL1 | KDM4E 784/4885MEN1 2252/4885KMT2A 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.